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ABSTRACT 
The Telomere is a nucleoprotein complex consisting of TTAGGG repeated sequences covered by 
specialized binding proteins termed shelterins masking the end of linear chromosomes and thereby 
protecting the end of the chromosome from genomic instability. Telomeres become progressively 
shortened during cellular replication and acts as a mitotic clock to confer a limited lifespan to normal 
cells. Telomerase reverse transcriptase (TERT) is responsible for lengthening telomeric DNA. The 
enzyme is silent in most normal cells due to the transcriptional repression of the TERT gene encoding 
the telomerase catalytic component. Numerous studies have demonstrated that the induction of TERT 
and subsequent activation of telomerase is prerequisite to malignant transformation of human cells 
through a telomere-lengthening mechanism. Moreover, evidence has recently shown that TERT or 
telomerase possesses many other biological activities contributing to tumor development and 
progression, therefore targeting TERT/telomerase has been suggested as a novel anti-cancer strategy. In 
the present project we studied telomere-lengthening-dependent and independent activities of TERT in 
malignant cells and explored therapeutic implications of TERT inhibition combined with other anti-
cancer strategies in acute myeloid leukemia (AML) and gastric cancer.  
Paper I is focused on whether TERT inhibition and telomere dysfunction is involved in the anti- tumor 
effect of the DNA methyltransferase inhibitor 5-azacytidine (5-AZA). We demonstrated that 5-AZA 
induced DNA damage and telomere dysfunction in AML cell lines coupled with diminished TERT 
expression, telomere attrition and cellular apoptosis. The results suggests that 5-AZA-mediated TERT 
inhibition and telomere dysfunction contributes to its anti-cancer activity. 
Paper II was aimed to define the relationship between the oncogenic cyclooxygenase (COX2) and TERT 
and to evaluate the synergetic anti-cancer action of simultaneous COX2 and TERT inhibition. We found 
that the depletion of TERT led to elevated COX2 expression by activating p38. The COX2 inhibitor 
celecoxib or TERT inhibition alone was insufficient to affect cell viability, however, the combination 
synergistically killed cancer cells both in vitro and in vivo. Thus, the combined application of  COX2 
and telomerase inhibitors may be more efficient in cancer treatment.  
About 30% of AML patients exhibit somatic mutations of FMS-like tyrosine kinase 3 (FLT3), the 
majority of which carry internal tandem duplication (ITD) in the juxtamembrane. FLT3 inhibitors have 
been developed for AML treatment. In paper III, we determined whether FLT3-ITD regulated TERT 
expression and whether TERT affected the therapeutic efficacy of FLT3 inhibitors. We found that the 
FLT3 inhibitor PKC412 down-regulated TERT expression in a MYC-dependent manner, while ectopic 
expression of TERT attenuated killing efficacy of PKC412 in AML cells.Altogether, our findings 
demonstrated that the interplay between TERT and FLT3ITD plays important roles in AML 
carcinogenesis and that FLT3 inhibitors, when combined with TERT inhibition, are  more efficient in 
the induction of AML cell apoptosis. 
In paper IV, we determined the effect of bortezomib on telomere homeostasis and its functional 
consequences. Bortezomib treatment inhibited TERT and telomerase expression, dysregulated shelterin 
proteins and shortened telomeres in AML and gastric cancer cell lines. The disrupted telomere structure 
triggered DNA damage response and cellular apoptosis. TERT overexpression significantly decreased 
DNA damage and telomere dysfunction and attenuated apoptosis mediated by bortezomib. Our findings 
collectively reveal a profound impact of bortezomib on telomere homeostasis/function, and down-
regulation of TERT expression and telomere dysfunction induced by bortezomib thus both contributing 
to its cancer cell killing actions. 
In summary, the present results provide novel insights of the biological functions of TERT/telomerase 
in malignant cells. In addition, the finding that the combination of telomerase inhibition with other anti-
cancer agents induced a robust and synergistic anti-tumor effect may have future important clinical 
implications  
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DNMTI DNA methyltransferase inhibitor 
DOK3  Docking Protein 3 
dNTP  Deoxy-ribonucleotide triphosphate 
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EGFR  Epidermal growth factor receptor 
ERK  Extracellular-signal-regulated kinases 
EVI1  Ecotropic virus integration site 1 (protein homolog) 
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HER2  Human epidermal growth factor 2 
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MAPK  Mitogen-activated protein kinase 
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MPN  Myeloproliferative neoplasm 
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NHEJ  Non-homologous end joining 
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UPS  Ubiquitin dependent Proteolysis System 
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1 INTRODUCTION 
1.1 Acute Myeloid Leukemia (AML)  
1.1.1 Definition 
Acute myeloid leukaemia (AML) is a malignant disorder characterized by abnormal 
hematopoietic cell growth and differentiation. The expansion of immature myeloid cells 
(myeloblasts) in the bone marrow and peripheral blood occurs at the expense of the normal 
production of their terminally differentiated counterparts such as red cells, platelets and 
neutrophils1,2. The clinical presentation of AML varies from an incidental finding on a routine 
blood test through to a life-threatening illness requiring immediate intervention. AML in the 
Western world is characterized by a slight male predominance and a median age at diagnosis 
of approximately 70 years. In AML excluding acute promyelocytic leukemia (APL) the age-
specific incidence rates rise gradually from around 40-50 years and more steeply from around 
age 60-64 years.  
1.1.2 Classifications 
There are two main systems that are used for classification of AML. In 1976, the French-
American-British (FAB) proposed the first classification system for AML based on leukemic 
blast morphology, lineage differentiation direction and the maturation degree3 (Table 1). This 
proposal was modified in 1985 and clinically used until the World Health Organization (WHO) 
released a new classification system which emphasizes more on the prognostic relevance of 
genetic abnormalities and classifies the AML based on genetic alterations, immunophenotypic 
changes, biological and clinical features4 (Table 2). The WHO classification was revised in 
2008 (Table 3). 
 
Table 1. FAB classification of AML 
FAB subtype  
M0 Undifferentiated AML 
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M1 AML without maturation 
M2 AML with maturation 
M3 Acute promyelocytic leukemia 
M4 Acute myelomonocytic leukemia (AMML) 
subtype 
M4 eos: Acute myelomonocytic leukemia 
with over 5% eosinophils 
M5 Acute monocytic  Leukemia 
Subtype 
M5a: Acute monoblastic Leukemia 
M5b: Acute monocytic Leukemia 
M6 Acute erythroblastic Leukemia 
M7 Acute megakaryoblastic Leukemia 
 
 
Table 2. WHO classification of AML in 2001 
1 AML with genetic abnormalities 
AML (M2) with t(8;21) translocation 
AML (M4eos) with a translocation or inversion of chromosome 16 (AMML Eos) 
AML with chromosome 11 abnormalities (secondary AML) 
AML (M3) with t(15;17) or rarely t(11;17) translocation (APML) 
 
2 AML with multilineage dysplasia 
With dysplasia in at least 50% of cells in at least two bone marrow cell lines 
 
 
 
3 Secondary AML 
Related to previous chemotherapy or radiation treatment 
 
4 AML not otherwise specified 
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AML that doesn’t fall into one of above groups, similar to FAB classification: 
Undifferentiated AML(M0), AML with minimal maturation (M1), AML with maturation 
(M2), AMML (M4), AMoL (M5), Acute Erythroid Leukemia (M6), Aute 
Megakaryoblastic leukemia (M7), Acute Basophilic leukemia, Acute Panmyelosis with 
fibrosis, Myeloid sarcoma 
 
5 Undifferentiated or biphenotypical acute leukemias 
Both lymphoid and myeloid features 
 
 
Table 3. WHO revised AML classification in 2008 
 
1 Acute Myeloid Leukemia with recurrent genetic abnormalities 
AML with t(8;21)(q22;q22), RUNX1-RUNX1T1   
AML with inv(16)(p13.1q22) or with t(16;16)(p13.1;q22); CBFB-MYH11  
APL with t(15;17)(q22;q12); PML-RARA  
AML with t(9;11)(p22;q23); MLLT3-MLL 
AML with t(6;9)(p23;q34); DEK-NUP214 
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
AML (Megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1  
Provisional entity: AML with mutated NPM1 
Provisional entity: AML with mutated CEBPA 
 
2 Acute myeloid Leukemia with myelodysplasia-related changes 
 
3 Therapy related myeloid neoplasms 
 
4 Acute myeloid leukemia, not otherwise specified 
AML with minimal differentiation 
AML without maturation 
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AML with maturation 
Acute Myelomonocytic leukemia 
Acute Monoblastic/Monocytic Leukemia 
Acute Erythroid Leukemia 
  Pure Erythroid Leukemia 
  Erythroleukemia, erythroid/myeloid 
Acute Megakaryoblastic Leukemia 
Acute Basophilic leukemia 
Acute Panmyelosis with myelofibrosis 
 
5 Myeloid Sarcoma 
 
6 Myeloid proliferations related to Down syndrome 
Transcient abnormal myelopoiesis 
Myeloid leukemia associated with Down syndrome 
 
7 Blastic plasmacytoid dendritic cell neoplasm 
 
1.1.3 Treatment 
Combination chemotherapy is the cornerstone of treatment and approximately 80% of patients 
below 60 years at diagnosis reach a complete remission (CR) which is essential for prolonged 
survival of AML patients.2 Induction therapy usually include (one or two courses) three days 
of an  anthracycline and five to seven days of cytarabine to achieve CR. CR is defined as less 
than 5% blasts in the bone marrow, and normal values for absolute neutrophil count (>1.0 x 
109/L) and platelet count (>100 x 109/L), and independence from red cell transfusion5. 
Postremission therapy often include consolidation therapy and allogeneic or sometimes 
autologous hematopoietic stem cell transplantation. AML is now cured in 35 to 40% of adult 
patients who are 60 years of age or younger at diagnosis and in 5 to 15% of patients who are 
older than 60 years of age. 
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AML is characterized by an enormous molecular heterogeneity and the prognostic importance 
of this biologic heterogeneity is well accepted. However, only recently has the translation of 
this new information slowly led to improved/targeted therapy.  
1.1.4 FMS-Like tyrosine kinase (FLT3) mutations in AML 
FLT3 is a type III Receptor tyrosine kinase (RTK) expressed in hematopoietic stem cells in the 
bone marrow. FLT3 facilitates cell growth, proliferation and differentiation of primitive 
hematopoietic progenitor cells6. FLT3-ITD is the somatic mutation of the FLT3 in the 
juxtamembrane domain and observed in approximately 20-25% of AML patients7-11. The 
juxtamembrane domain is autoinhibitory, and thus the ITD mutation disrupts this autoinhibitory 
function and constitutively activates the enzyme12,13. FLT3-ITD is considered as driver in the 
development of AML and a predictor for poor outcome in AML patients.7-11,14-19 
1.1.5 FLT3 inhibitors 
In recent years, small-molecule tyrosine kinase inhibitors (TKIs) have been synthesized to 
target FLT3 and are now under evaluation in clinical trials for induction chemotherapy and 
postremission therapy20,21. These TKIs include tandutinib22, lestaurtinib23, midostaurin24, 
sorafenib25, sunitinib and quizartinib.  Resistance to treatment is always a major obstacle in 
AML therapy26-28. With respect to FLT3 inhibition the underlying mechanism involves the 
occurrence of new mutations in the FLT3 genomic region. However, these new mutations were 
only detected in a part of FLT3TKI resistant patients. 
 
1.2 Telomere 
1.2.1 Telomere structure and shelterin proteins 
Human telomeres are composed of tandem repeats of TTAGGG DNA sequences, usually 
extending 10-15kb. Telomeres are double stranded repeats with a single strand 3’ G rich tail. 
The overhang can then invade the double strand telomere tract and forms a lasso-like structure 
termed telomeric loop (T-Loop)29,30. The single strand tail acts as the docking site for binding 
protective capping proteins, like POT1 (see below), to maintain genomic stability (Figure 1).  
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Figure 1. Telomere protects the chromosome end and shelterin proteins bind to the telomere 
 
 Human telomeres are bound by a specific group of six proteins, termed shelterin proteins: 
telomere repeat binding factor 1 (TRF1) and 2 (TRF2), protection of telomeres 1 (POT1), 
repressor/activator protein 1 (RAP1)31, TRF1-interacting nuclear protein 2 (TIN2) and TIN2 
interacting protein 1 (TPP1)32,33. The proper combination of shelterin proteins as well as the 
sufficiently long telomere protect chromosome ends from DNA damage, degradation, genomic 
destabilization34 and genomic recombination or fusions35. The shelterin proteins form the 
bridge to bring together the binding proteins of ssDNA and dsDNA and protects the 
chromosome end from being recognized as DNA damage or breaks. TRF1 and TRF2 bind to 
the double strand telomere, each of them contains the TRFH domain for homodimerization36 
and Myb domain for dsDNA telomere binding37-39.  
POT1 binds the single strand telomere part with the DNA-binding domain (DBD) (Figure 2), 
formed by two oligonucleotide/oligosaccharide-binding fold (OB-fold) elements40-45. The 
further formation of the ternary complex with TPP1 enhances the interaction46,47. The crucial 
bridging unit TIN2 not only joins the TRF1 and TRF2 but also puts TRF1, TRF2, POT1 and 
TPP1 together. As TRF1 cannot heterodimerize or interact with TRF2, the linking role of TIN2 
seems necessary. N-terminal of TIN2 recruits TPP1 to the telomere by binding its C-terminal48-
52. 
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Figure 2. POT1 binds to single strand DNA of telomere53 
1.2.2 Hayflick limit and end replication problem 
Fifty years ago, Hayflick and Moorhead discovered that the proliferative capacity of somatic 
cells like normal human fibroblast cells were intrinsically limited54. After about 60-80 doubling 
cycles, cultured fibroblast cells stop dividing and adopt a senescent phenotype. This 
proliferative limit, known as hayflick limit or replicative senescence55-57, is mainly caused by 
over-shortened telomeres. On the other hand, the DNA polymerase can only synthesize DNA 
from 5’ to 3’, incapable of filling the gap left behind by the 5’ end, which leads to chromosome 
end replication problem58.  
1.2.3 Telomere function, genomic instability and cancer 
Telomere conceals the linear chromosome from being detected as DNA Double Strand Break 
(DSB). Critical telomere shortening and disruption in telomere structure are important causes 
of genomic instability. When telomere length reaches below the minimal functional length, or 
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the telomere become uncapped, it will be recognized as the DSB, and thereby DNA damage 
response (DDR) is triggered59. The uncapped telomere will be repaired by the homologous 
recombination or NHEJ (non-homologous end joining) and leads to end-to-end fusion, which 
could be achieved, via either classic non-homologous end joining (C-NHEJ) or alternative non-
homologous end joining (A-NHEJ) or other alternative pathways60-62.  The end-to-end fusion 
between sister or other different chromatins leads to breakage-fusion-bridge cycle. The 
breakage-fusion-bridge cycle can result in deletions, amplifications and rearrangements of 
chromosomes that are often observed in cancer cells. This cycle will continue until the telomere 
healing occurs. 
1.2.4 Telomere dysfunction 
Studies have demonstrated that the shortest telomere length rather than traditionally thought the 
average telomere length determines the cell response. In human fibroblasts, the threshold of 
senescence is about five repeats short telomeres. Critically short telomeres would be 
dysfunctional and elicit the DNA damage repair activation. Phenotypically, co-localization  of 
the telomere with the DNA damage repair proteins like 53BP1 or rH2AX would be expected. 
1.3 Telomerase 
1.3.1 Telomerase and its components 
Telomerase is a specialized DNA polymerase responsible for synthesizing TTAGGG DNA 
repeats onto the chromosome ends. Telomerase holo-enzyme consists of two conserved 
components: the core catalytic protein TERT63,64 and the RNA template TERC. TERT and 
TERC are assembled in the Cajal body to form the functional ribonucleoprotein enzyme 
complex65 (Figure 3). By synthesizing telomeric DNA (tandem repeated TTAGGG sequence), 
telomerase compensates for the gradually lost telomere and provides solutions to the 
chromosome end replication problem. Telomerase expression is low in most somatic cells66, 
while high in germline and stem cells67. 
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Figure 3. Telomerase is assembled in Cajal body and delivered to the telomere 
1.3.2 TERT 
The reverse transcriptase subunit TERT contains about 1000 amino acids68 and contains 3 major 
domains: the telomerase essential domain (TEN), TERT RNA binding domain (TRBD), and 
the reverse transcriptase domain with finger, palm and thumb63. The fingers and palm recognize 
the RNA arm and fit the template into catalytic center. The thumb recognizes and stabilizes the 
DNA primer. The T and CP pockets bind the template boundary element to ensure repeat 
addition according to the RNA template only69. The TEN domain anchors on the telomeric 
DNA and uses the inside DAT motif for telomerase recruitment70,71.  
1.3.3 TERC 
The human TERC templates for telomere synthesis is 451 nucleotide long72. TERC has a 
template boundary element that limits reverse transcriptional range73-75. In the site of the 
catalytic center, the triple helix and pseudoknot orientate the primer-template and plays a 
certain catalytic role76-78. TERC also functions by loading the template into active center and 
aid template relocation during multi rounds of repeat addition79,80.  TERC binds to telomerase 
by the template-pseudoknot domain and CR4-CR5 domain81-83. The distinct RNA structure and 
elements of TERC provide possibility of telomerase accessory protein binding. H/ACA box on 
3’ end of TERC could bind dyskerin, NOP10, NHP2 and GAR184,85. Another important motif 
on the 3’ end is Cajal box motif (CAB), which binds telomerase Cajal body protein 1 
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(TCAB1/WDR79) and localizes the TERC into the Cajal body for assemble of telomerase 
package.  
1.3.4 Telomerase inhibition in cancer 
Telomerase plays very important roles in carcinogenesis and thus, inhibition of telomerase 
should be considered as one anti-cancer approach. Several telomerase inhibitors have been 
developed such as BIBR1532, GRN163 and GRN163L. Recently, GRN163L (imetelstat) has 
been shown to deliver fast and durable hematologic effects in essential thrombocythemia 
patients86.  
1.4 DNA methylation 
1.4.1 Chemical nature of DNA methylation 
DNA methylation occurs at 5’ carbon of the cytosine ring by covalent addition of a methyl 
group, which occurs at the major group of the genomic DNA strand and blocks the 
transcription87.  
DNA methylation commonly takes place in cytosine in CpG dinucleotides. These CpG 
dinucleotide clusters in gene promoter regions, where transcription is initiated, silence the genes 
or non-coding genomic regions88.  
In normal cells, heterochromatin like pericentromere regions are heavily methylated and 
transcriptionally silenced. In females, the inactivated X chromosome is also heavily methylated. 
Besides, some imprinted genes that only express maternal or paternal alleles also rely on DNA 
methylation88,89. 
1.4.2 DNA methyltransferase (DNMT) 
DNA methylation relies on DNMTs, with three major isforms: DNMT1, DNMT3A and 
DNMT3B. DNMT1 is mainly involved in the maintenance of existing methylation pattern, 
while DNMT3A and DNMT3B target unmethylated nucleotides including CpG sites, which is 
enriched in CpG islands, and large repetitive sequences like centromeres and retrotransposon 
elements. 
11 
 
1.4.3 DNA methylation in cancer 
Cancer epigenome is characterized by altered DNA methylation patterns. Cancer cells manifest 
global hypomethylation and local hypermethylation. DNA hypomethylation in cancer occurs 
in repetitive sequences, low density CpG regions90-97, retrotransposons, lamin associated 
domains98-101, introns, etc. This hypomethylation will lead to genomic instability through 
chromosome rearrangement and translocation to other genomic regions. Hypomethylation also 
leads to activation of oncogenes and losses of genomic imprinting. 
Another apparent epigenetic change in cancer is the hypermethylation in CpG island promoter 
regions102-104 which silences the tumor-suppressor genes, such as the breast cancer 1, early onset 
(BRCA1), CDKN2A/p16INK4A (cyclin dependent kinase inhibitor 2A), MLH1 and VHL, and 
CpG island shores105-107. Hypermethylation occurs in hematopoietic malignances like 
myelodysplastic syndromes  (MDS) and contributes to leukemic transformation108-112.  
1.4.4 DNA methylation inhibitors  
The DNA methylation inhibitors include 5-azacitidine (5-AZA)113, decitabine, zebularine114, 
NPEOC-DAC115, CP-4200116,117, and RX-3117118-120. They induce the recovery of methylation 
silenced genes in cancer and lead to apoptosis and growth arrest in cancer cells. Both 5-AZA 
and decitabine have shown positive clinical effects in subsets of AML and MDS patients121. 
 
1.5 The ubiquitin dependent proteolysis system (UPS) and 
proteasome inhibition in cancer  
1.5.1 UPS function 
The UPS is the main player in regulated protein degradation in prokaryotic cells and functions 
critically in regulation of variety of pathways, including apoptosis122, proliferation123, DNA 
repair124,125, transcription126, etc. UPS initializes an enzymatic cascade via minimal of 
Ubiquitin-activating enzyme E1, ubiquitin-conjugating enzyme E2 and ubiquitin ligase E3 
activities. Ubiquitin-activating enzyme E1 forms a highly energetic thioester bond between 
glycine residue of ubiquitin and cysteine residue within E1 itself, utilizing energy from the ATP 
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hydrolysis. This energized ubiquitin is then transferred to the cysteine of the ubiquitin 
conjugating enzyme E2. Finally, the E2 cooperates with E3, the ubiquitin ligase, to transfer this 
high energy ubiquitin to the lysine of target protein. This initial ubiquitin acts as the acceptor 
for further ubiquitin modification and forms a polyubiquitin chain onto the target protein. The 
ubiquited proteins are then targeted towards the proteasome. This proteasome is a large 
complex responsible for degradation of large variety of intracellular proteins.  
1.5.2 Proteasome inhibition in cancer  
The proteasome pathway takes part in cell proliferation and anti-apoptosis, especially involving 
the pro-oncogenic NF-B pathway, which plays vigorous roles in many cancer types. IBs 
retains the NF-B within cytoplasm and keeps it inactive. When polyubiquitylated, 
polyubiquitinated IBs will be degraded by the proteasome and thus unleash the NF-B. The 
proteasome inhibitor bortezomib (Velcade/PS-341)127-132 targets the active sites of 20S 
proteasome reversibly and prevent the degradation of IB, thus holding NF-B in leash133. The 
inhibition of NF-B reduces the pro-inflammation gene expression and results in elevated 
expression of the cyclin-dependent kinase inhibitors P21Cip1 and  P27Kip1, leading to apoptosis 
of tumor cells. Aside from this, evidence shows that bortezomib also induces endoplasmic-
reticulum stress thereby increasing cell death. 
1.6 Cyclooxygenase (COX), COX2 inhibition and cancer 
1.6.1 Cyclooxygenase  
Cyclooxygenase (COX) is a key enzyme responsible for inflammation, converting arachidonic 
acid to prostaglandin and thromboxane134. COX has at least two isoforms, COX-1135 and COX-
2136. While COX-1 is constitutively expressed in most tissues for maintaining physiologic 
homeostasis, COX-2 is induced by inflammatory stimuli but not normally present except in 
CNS137 and kidneys138 including cytokines and growth factors. Studies have shown that COX-
2 contributes to cancer development and progression in various types of malignancy.  
. 
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1.6.2 COX2 inhibitors and cancer 
COX2 plays an important role in suppressing apoptosis and promoting cell survival via 
PI3K/AKT139,140, ERK141,142, cAMP142, EGFR143,144, RAS-MAPK signaling145,  
COX2/PGE2/EP4 axis146 and promote tumor survival. Thus, COX2 specific inhibitors147-149 
have been utilized in cancer therapy and some in clinical trials, such as celecoxib150,151, 
rofecoxib152-155, nimesulide, etc. 
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2 AIMS OF THE STUDY 
The overall objective of the present study is to define the role of telomerase in oncogenesis and 
to identify potential novel therapeutic strategies for human malignancies. Specifically, the study 
is aimed at 
 probing the effect of the DNA methylation inhibitor 5-AZA on telomere function, and 
exploring mechanisms of DNMT inhibitors’ action  
 defining the effect of TERT inhibition on COX2 expression and exploring the 
synergistic anti-tumor efficacy of COX2  and TERT inhibition; 
 probing the functional interplay between FLT3-ITD and telomerase in AML; 
 exploring the mechanism underlying the anti-cancer effect of bortezomib and its effect 
on telomere homeostasis and function. 
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3 MATERIALS AND METHODS 
3.1 Cell culture 
Cells grew in 10% fetal calf serum-containing RPMI-1640 (Life Technologies, Paisley, 
Scotland, UK) with addition of 2 mM L-glutamine and antibiotics (50 mg/mL penicillin, and 
50 mg/mL streptomycin) in a humid atmosphere at 37°C/5% CO2. 
In PAPER I, AML cell lines KG1A and HEL were used. 
Human gastric cancer cell lines AGS (ATCC, 2007) and BGC-823 (Beijing Cancer Institute, 
China, 2008), the cervical cancer cell line HeLa (ATCC, 2001), normal human skin fibroblasts 
and osteosarcoma cell line U2OS were used in PAPERⅡ.  
In PAPER Ⅲ ,FLT3-ITD-harboring AML cell lines MV4,11 and MOLM-13, acute 
promyelocytic leukemia cell line HL60 and cervical cancer cell line were used. 
In PAPER Ⅳ, the leukemia cell line HEL and the gastric cancer cell line BGC-823 were 
cultured. 
3.2 Primary AML cell separation and culture 
Primary AML cells were derived from five AML patients. Peripheral blood was drawn into 
heparinized glass tubes and leukemic cells were isolated by Lymphoprep gradient 
centrifugation (Nycomed, Oslo, Norway), and subsequently incubated in complete medium in 
the absence or presence of 5-AZA as described above. 
3.3 Small interfering RNA transfection  
Chemically modified Stealth control and TERT siRNAs were bought from Invitrogen. 
Cells were incubated in 6-well plates, with density 1.0 ×105 cells per well, overnight and then 
transfected with siRNA (sequence in table) using Lipofectamine 2000 (Invitrogen, Carlsbad, 
CA, USA) according to the manufacturer’s instruction.  
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Table 4. SiRNA sequence 
 Sequence 
Control 50 -CCUACAUCCCGAUCGAUGAU- GUUGA-30 
TERT 50 -AGGCACUGUUCAGCGUGCU- CAACUA-30 
 
 
3.4 Lentivirus infection 
To knock down TERT expression, we infected cells with a lenti-viral vector encoding TERT 
siRNA (Invitrogen) and the cells were maintained in puromycin-containing medium (2µg/ml) 
48h post infection 
A lenti-III-HA-GFP-TERT vector was constructed and a Lenti-BMN-GFP vector (a gift from 
Rudbeck Laboratory, Department of Immunology, Genetics and Pathology of Uppsala 
University) was used as control. The lentiviral vector was packaged in 293FT cells and 
supernatant collected to infect HEL cells. The cells were selected using puromycin (2 μg/ml). 
3.5 Drug treatment 
To inhibit COX2, COX1 and p38 mitogen-activated protein kinase (MAPK) activity, BGC-823 
cells were treated with the specific COX2 inhibitor celecoxib (50 μM), aspirin (0.4 mM) and 
p38 MAPK inhibitor SB203580 (10 or 20 mM) for different time periods (all from Sigma-
Aldrich, St Louis, MO, USA), respectively. 
The DNA methylation inhibitor 5-AZA was bought from Sigma-Aldrich (St. Louis, USA) and 
exponentially growing cells were cultured in the presence and absence of 5-AZA (0, 0.5, 1, 2 
and 5 μM) for up to 144 hours or 6 days. Culture medium was replaced with freshly prepared 
5-AZA-containing medium every second day.   
The specific FLT3 inhibitor PKC412 (Sigma-Aldrich, Buchs, Switzerland) was diluted in 
DMSO and cells were incubated with different concentrations of PKC412 for various time 
periods. 
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Bortezomib was bought from Selleck Chemicals (Houston, TX, USA) and exponentially 
growing cells were incubated with bortezomib at different concentrations for various time 
periods. 
3.6 RNA extraction, reverse transcription and quantitative real-
time PCR (qPCR) 
Total cellular RNA from cells with different treatments was extracted using Trizol (Life 
Technology, Paisley, Scotland, UK). 
cDNA was synthesized using random primers (N6; Amersham, Buckinghamshire, UK), and 
M-MLV reverse transcriptase. 
qPCR was carried out in an ABI7700 sequence detector (Applied Biosystems, Foster City, CA, 
USA) using SYBR Green kit (Applied Biosystems) and the following primers:  
TERT, β2-M in PAPER I; 
TERT, COX2, COX1, β2-M in PAPERⅡ; 
TERT, c-MYC, c-KIT, DOK3, NID-1 and SULF2 in PAPER Ⅲ; 
TERT, TERC, TRF1, TRF2, TPP1, POT1, RAP1 and TIN2 in PAPER Ⅳ.  
Levels of TERT, COX2, COX1, TERC, TRF1, TRF2, TPP1, POT1, RAP1, TIN2, c-MYC, c-
KIT, DOK3, NID-1 and SULF2 mRNA were calculated based on the cycle threshold (CT) 
values and normalization of human β2-M expression. 
Table 5. Q-PCR primer sequences and Primer sequences for telomere length analyses 
Gene Forward Reverse 
TRF1 5’-GCTGTTTGTATGGAAAATGGC-3’ 5’-CCGCTGCCTTCATTAGAAAG-3 
TRF2 5’- GACCTTCCAGCAGAAGATGCT-3’ 5’-GTTGGAGGATTCCGTAGCTG-3’ 
TPP1 5’- CCCGCAGAGTTCTATCTCCA-3’ 5’-GGACAGTGATAGGCCTGCAT-3’ 
TIN2 5’- GGAGTTTCTGCGATCTCTGC-3’ 5’-GATCCCGCACTATAGGTCCA-3 
POT1 5’-TGGGTATTGTACCCCTCCAA-3’ 5’-GATGAAGCATTCCAACCACGG-3’ 
RAP1 5’-CGGGGAACCACAGAATAAGA-3’ 5’-CTCAGGTGTGGGTGGATCAT-3’ 
TERC 5’-TCTAACCCTAACTGAGAAGGGCGTAG-3’ 5’-GTTTGCTCTAGAATGAACGGTGGAAG-3’ 
TERT 5’-CGGAAGAGTGTCTGGAGCAA-3’ 5’-GGATGAAGCGGAGTCTGGA-3 
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β2-M 5'-GAATTGCTATGTGTCTGGGT-3’ 5’-CATCTTCAAACCTCCATGATG-3’ 
COX2 5’ -GCCCAGCACTTCACGCATCAG-3’ 5’ -AGACCAGGCACCAGACCAAAGACC-3’ 
COX1 5’-CGGCTGCAGCCCTTCAATGAGT-3’ 5’ -CTCTCCCCAAAGATAGAGTTTGGA-3’ 
c-MYC 
5'-TACCCTCTCAACGACAGCAGCTCGCCCAACTCCT-
3' 
5'-TCTTGACATTCTCCTCGGTGTCCGAGGACCT-3' 
c-KIT 5’-TCATGGTCGGATCACAAAGA-3’ 5’-AGGGGCTGCTTCCTAAAGAG-3’ 
DOK3 5’-GTCCCCATGGAGGAAAACTC-3' 5’-AAGTGGTAGGGCCAGCTGTA-3’ 
NID-1 5’-AGGAGCTCTTTCCCTTCGGC-3’ 5’-CGGGGGTTCACTCGTAGCAA-3’ 
SULF2 5’-CCGCCCAGCCCCGAAACC-3’ 5’-CTCCCGCAACAGCCACACCTT-3’ 
Primer sequences for telomere length analyses 
Tel1b 5′-CGGTTTGTTTGGGTTTGGGT-TTGGGTTTGGGTTTGGGTT-3′ 
Tel2b 5′-GGCTTGCCTTACCCTTACCCTTACCC-TTACCCTTACCCT-3′ 
HBG3 5′-TGTGCTGGCCCATCACTTTG-3′ 
HBG4 5′-ACCAGCCA-CCACTTTCTGATAGG-3′ 
3.7 Telomerase activity assay 
Telomerase activity was assessed using a commercial Telomerase PCR ELISA kit (Roche 
Diagnostics Scandinavia AB, Stockholm, Sweden) as recommended by the manufacturer. For 
each assay, 1 µg of protein was used, and 26 PCR cycles were performed after the telomerase-
primer elongation reaction. The PCR products were detected using ELISA color reaction and 
the level of telomerase activity was expressed as absorbance in arbitrary units. 
3.8 Cell cycle and apoptosis detection with flow cytometry 
In PAPERⅠAML cells were treated with different concentrations of 5-AZA for three days, 
and then harvested and fixed in ethanol followed by PI staining. The PI fluorescence was 
measured with a FlowCytometer (Beckman Coulter). For each sample 1 × 106 cells were 
measured. Data analysis was performed with Kaluza® Flow Analysis Software. The control 
gate was set based on the negative control. 
In PAPERⅡBGC-823 cells transfected with control and TERT siRNA were incubated with 
and without celecoxib and harvested after 4 days. The cells were fixed with 70% ethanol at 
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+4℃ overnight and stained with RNase A (0.5 mg)-containing propidiumiodide (50 mg/ml) 
Cell cycle distribution was determined using flow cytometry with ModFit (BD Biosciences, 
Franklin Lakes, NJ, USA). 
In PAPERⅢ Stable MOLM-13 cells were transfected with control pBMN or TERT-expressing 
lentiviral vectors, treated with 0.1 μM PKC412 and harvested after 24 hrs then fixed with 70% 
ethanol at + 4℃ overnight and stained with RNAse A (0.5 μg) containing PI, 50 μg/ml. Cell 
cycle distribution was determined using flow cytometry with ModFit. 
In PAPER Ⅳ cells were treated with bortezomib, and then harvested for apoptosis assay. The 
cells were stained with a kit from BD Biosciences and analysed using a FlowCytometer (BD). 
For each sample 1 × 106 cells were measured. The control gate was set based on the negative 
control. 
3.9 Western blot 
Total cellular proteins were extracted with RIPA lysis buffer.  
In PAPERⅡ for the assessment of phosphorylated p38 MAPK, cells were washed once with 
sodium orthovanadate-containing buffers to inhibit phosphatases before RIPA buffer lysis. 
20𝜇g proteins were subjected to SDS-polyacrylamide gel electrophoresis and transferred to a 
nitrocellulose membrane. The membranes were probed with the specific antibodies against 
COX2 (Cayman chemical, Ann Arbor, MI, USA), Phospho-p38 MAPK (Thr180/Tyr182), p38 
MAPK (Cell Signaling Technology, Billerica, MA, USA) or 𝛽-actin (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) and then with secondary anti-mouse or rabbit 
horseradish peroxidase-conjugated IgG (Bio-Rad, Hercules, CA, USA) 
In PAPERⅢ proteins were probed with the specific antibody against FLT3, p- FLT3, Akt and 
p-Akt (Cell Signalling Technology, Boston, USA) or c-MYC (Santa Cruz Biotechnologies) 
followed by anti-mouse or rabbit horseradish peroxidase-conjugated IgG.  
In PAPER Ⅳ proteins were probed with the specific antibodies against TRF1 (Sigma-Aldrich, 
St. Louis, MO, USA, T1948), TFR2 (Novus, Littleton, CO, USA, #NB110-57130), POT1 
(Novus, NB500-176), Caspase3 (Cell Signaling Technology, Danvers, MA, USA, #9665), or 
Bcl-2 (ProteinTech, Wuhan, China, #12789-1-AP) followed by anti-mouse or rabbit 
horseradish peroxidase-conjugated IgG. 
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β-actin immunoblotting was performed in parallel as a loading control. 
The membrance were then developed by chemiluminescence (SuperSignal West Pico 
Chemiluminescent Substrate, Thermo Scientific). 
 
3.10 Promoter activity assay  
In PAPERⅡ, to determine the effect of TERT knock-down on the COX2 promoter reporter 
activity, we transfected control and TERT-depleted BGC-823 cells with the COX2 reporter 
construct, in which the COX2 core promoter sequences ( -327/ +59) were inserted up-stream 
of a luciferase-encoding DNA fragment (Katsukawa et al, 2010; Inoue and Nakata, 2011; kindly 
provided by Dr Hiroyasu Inoue, Nara Women’s University, Japan). The COX2 promoter-driven 
luciferase activity was determined using a dual luciferase reporter assay system (Promega, 
Madison, WI, USA) 48h post transfection, and the target promoter-driven firefly luciferase 
activity was normalised to the renilla activity included in the kit. 
In PAPERⅢ  The TERT promoter reporter plasmid p181wt harboring the core promoter 
sequence of the TERT 5'-flanking region and its mutant variant (p181MYC-) lacking the 
functional c-MYC motifs (E-boxes) were described previously. Cells cultured in 24-well plates 
at 0.5×106 cells /well were transfected with p181wt and p181MYC- plasmids using 
Lipofectamine2000 (Life Technology) according to the manufacturer's protocol, followed by  
treatment with PKC412. Luciferase activity in the cell lysates was determined by using a dual 
luciferase reporter assay system (Promega, WI) 24 hours post-transfection of the promoter 
reporter. 
3.11 Puro. Cre-TERT promoter-driven-GFP plasmid and lenti-III-
HA-GFP-TERT vectors 
The h3.4k-GFP plasmid containing 3.4kb TERT promoter (+1 to -3405, ATG as +1) was 
obtained from Dr. Pei-Rong Huang (National Taiwan University), and the 3.4kb TERT 
promoter fragment was inserted into a pPuro. Cre empty vector (Addgene) upstream of GFP 
gene. For pLenti-III-HA-GFP-TERT vector construction, pLenti-III-HA empty vector was 
21 
 
bought from Applied Biological Materials Inc. (BC, Canada), a 4.5kb GFP-TERT fragment 
was cut from pBabe-hygro-GFP-TERT (Addgene) and inserted into pLenti-III-HA. A control 
plasmid, pLenti-BMN-GFP was a gift from Rudbeck Laboratory, Uppsala University. The 
vectors were then packaged and viral particles collected to infect AML cells to make TERT 
promoter-driven GFP cells and TERT-over-expressed cells. 
3.12 Quantitative Fluorescence In situ Hybridization (Q-FISH) 
BGC-823 cells were transfected with control and TERT siRNA and the metaphase cells 
harvested at 72h. Telomere length was determined using quantitative FISH (Q-FISH) with PNA 
(CCCTAA)3 probe. The signal intensity in 50 cells was determined using NIS software (Nikon, 
Stockholm, Sweden) and expressed in arbitrary units. 
3.13 Immuno Fluorescence In Situ Hybridizaiton (Immuno-FISH) 
Briefly, cells were harvested and cytospined onto Superfrost plus slides (Thermo Scientific), 
fixed with 4% paraformaldehyde, permeabilized with Triton PBS for 20 mins and blocked with 
serum free Block (DAKO, Glostrup, Denmark). The slides were then incubated with 53BP1 
antibody (Bethyl Inc., Montgomery, Texas, USA) followed by incubation with Alexa 594 
secondary antibody (Jackson Labs Technologies Inc., Los Gatos, CA, USA). The slides were 
treated with frozen and thawed cycle in liquid nitrogen, and incubated in 0.1N HCL for 10 min. 
The PNA-telomere probe (PANAGENE Inc., Daejeon, Korea) was added. The slides were then 
subjected to 85℃ denaturation for 10 min and 30℃ hybridization for 2h and a following 
washing procedure. High-resolution images were collected using Leica Confocal TCS SP5 with 
488 nm and 594 nm sequential laser scan. Z stack images was acquired with slide interval 
recommended optimization and between-stack mode. The co-localization of 53BP1 and 
telomere signals was examined and analyzed on each layer by two separate independent persons 
in a double-blind manner.  
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3.14 Flow FISH for telomere length assay 
Flow FISH was performed according to previous protocols by Baerlocher et al.  with minor 
modifications. Cells from calf thymus were kindly donated from the butchery Ö-slakt AB 
(Värmdö, Stockholm). Stained cells were captured with Gallios flow cytometer (Beckman 
Coulter) and analyzed using the Kaluza software (Beckman Coulter, Caguas, PR, USA). For 
normalization, fluorescent MESF-FITC beads (Bangs Laboratories, Fishers, IN, USA) were 
used and the fluorescent signal was quantified using the QuickCal v.2.3 data analysis program 
(Bangs Laboratories). 
3.15 Subtelomeric DNA methylation at chromosome 4p 
Genomic DNA, extracted from control and TERT- over-expressed HEL cells with or without 
5-AZA, was subject to bisulfite conversion using an EZ DNA Methylation-Gold Kit (ZYMO 
RESEARCH, Irvine, CA, USA). PCR primers specific to the subtelomere region of 
chromosome 4p was used to amplify the target region. The obtained PCR products were then 
sequenced from both directions. Two independent experiments were performed. 
3.16 cDNA array 
MOLM-13 cells infected with control pBMN or TERT-expressing lentiviral vectors were 
treated with 0.1 μM PKC412 for 12 hrs and total RNA extracted. The affymetrix Human Gene 
1.0 ST Array was performed. The fold change in gene expression between DMSO- and 
PKC412-treated cells was then calculated. 
3.17 Mouse xenograft model  
BGC-823 cells were infected with control and siTERT lenti-viral vectors were collected, 2.0 x 
106 cells were suspended in 100 ml PBS. The cells were then subcutaneously injected into nude 
mice (Shanghai Slac Laboratory Animal Co. Ltd., Shanghai, China) at the right back. The mice 
harbouring control and TERT siRNA BGC-823 cells were divided into two groups each, and 
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one of them was fed with celocoxib containing drinking water (1.5 mg/ml), based on studies of 
prostate cancer tumour model. Therefore, there were a total of four groups (10 mice per group): 
(1) control siRNA group; (2) control siRNA plus celecoxib group; (3) TERT siRNA group; (4) 
TERT siRNA plus celecoxib group. Mice were euthanized after 3 weeks and tumours were 
isolated for the measurement of weight, size and other analyses. 
3.18 Statistical analyses 
In PAPERⅠ, Student’s T-test was used to compare cell numbers, apoptotic cells, TERT mRNA 
levels and telomere length between control and 5-AZA-treated AML cells.  
In PAPERⅡ, Mann–Whitney U-test or Student’s T-test was used for analyses of differences 
between experiment groups.  
In PAPERⅢ, The comparison of mRNA expression, promoter activity, telomerase activity and 
cell cycle analysis between control and experimental groups was made using a Student's T-test 
or One- way ANOVA followed by LSD test. P value less than 0.05 is considered significant.  
In PAPER Ⅳ, Student’s T-test or Mann-Whitney U test was used to compare cell numbers, 
apoptotic cells, TERT, TERC and shelterin protein mRNA levels and telomere length between 
control and bortezomib-treated cells.  
All the tests were two-tailed and computed using SPSS or SigmaStat 3.1 software (Systat 
Software, Inc., Richmond, CA, USA) software. P values less than 0.05 were considered 
statistically significant. 
3.19 Ethics 
Study Ⅰwas approved by the regional ethical review board in Stockholm, Sweden. 
StudyⅡ was  approved by Chinese Ethical review board in Jinan, China. 
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4 RESULTS AND DISCUSSION 
4.1 Paper I: The DNMT inhibitor induced telomere dysfunction 
and the overexpression of telomerase could attenuate its anti-
cancer efficacy  
4.1.1 The DNMT inhibitor 5-AZA leads to apoptosis and induces DNA 
damage and telomere dysfunction 
HEL cells seem to be more sensitive to 5-AZA treatment than KG1A cells with almost complete 
growth arrest at a concentration of 0.5µM. The trypan blue staining showed a progressive 
decline in HEL cell viability with increased concentrations of 5-AZA and longer incubation 
time. PI staining using  flow cytometric analysis showed that the declined viability was due to 
increased cellular apoptosis. 
Previous publications revealed DNA damage response in 5-AZA treated cancer cells156,157. We 
wanted to investigate this phenomena in AML cell lines by determining the focal formation of 
53BP1 protein foci, a very well established DNA damage response marker. 53BP1 signals were 
detected in 5-AZA treated cell lines KG1A and HEL and were absent in corresponding 
untreated control cells.  
Our next question was whether 5-AZA treatment could induce telomere dysfunction. Here we 
utilized the co-localization of  the DNA damage marker protein, 53BP1 and the telomere signals 
to demonstrate the dysfunctional telomere induced foci (TIF) using immune-fluorescent in situ 
hybridization (Immuno-FISH). Telomeres were shown as green signals. In both AML cell lines 
(KG1A and HEL) treated with 5-AZA, the DNA damage signal 53BP1, red dots, was detected 
while absent in control untreated AML cell lines. In addition, the merged image showed the co-
localization of 53BP1 foci on the telomere signal in 5-AZA exposed cells and this co-
localization was rarely found in untreated cells (Figure 4).  
In order to find the reason for telomere dysfunction, we measured telomere length. The two 
AML cell lines (KG1A and HEL) were exposed to 2.0 µM and 5.0 µM 5-AZA for 72h and then 
analyzed with Flow-FISH. Both cell lines exposed to 2.0 µM 5-AZA exhibited slightly shorter 
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telomeres compare to untreated cells while apparent attrition of telomeres became apparent at 
5.0 µM exposure 5-AZA. 
Previous reports indicated the contribution of subtelomeric regions to the telomere stability, as 
the methylation status of these regions locally affects the chromatin structure. Methylation 
specific PCR together with Sanger sequencing were performed to examine the subtelomere 
region methylation configuration of chromosome 4p. Out of a total of 31 CpGs in the amplicon, 
25 were methylated in untreated HEL cells, 24 of which remained methylated after 5-AZA 
exposure. These results illustrate the resistance of subtelomeric regions to DNMT inhibitors.  
 
Figure 4. 5-AZA leads to apoptosis and induces DNA damage and telomere dysfunction 
 
4.1.2 5-AZA suppresses TERT expression in AML cell lines 
To further explore the mechanism of telomere shortening, we analysed telomerase expression 
and telomerease activity in 5-AZA treated KG1A and HEL cell lines. After 5-AZA exposure in 
KG1A cells, TERT mRNA expression was significantly downregulated in a dose dependent 
manner. The same results were observed in the 5-AZA treated HEL cell line.  
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In addition, the telomerase activity was also diminished but to a lesser extent probably due to a 
longer half-life of telomerase. 
To further investigate whether the results achieved in  AML cell lines could be duplicated in 
AML primary cells  we tested the 5-AZA effect on primary cells obtained from newly 
diagnosed AML patients. Similar to the cell line experiments telomerase expression was 
downregulated after 5-AZA exposure in of all the five patients.  
4.1.3 Ectopic expression of TERT attenuates telomere dysfunction  
Given the above observation, we would like to rule out whether ectopic expression of TERT 
could antagonize the 5-AZA effect. We constructed the TERT overexpression HEL cell line 
with lentiviral TERT expression construct, which lead to two-fold increase in telomerase 
activity and abolished the 5-AZA effect on telomerase expression. After ectopic expression of 
TERT, 5-AZA induced apoptosis was decreased and the number of TIFs declined as compared 
to control cells (Figure 5). 
.  
Fiugre 5. Ectopic expression of TERT attenuates telomere dysfunction 
 
In summary, we demonstrate that 5-AZA could depress TERT expression in AML cells, shorten 
telomeres which led to telomere dysfunction which subsequently induced apoptosis. 
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Meanwhile, ectopic expression of TERT could antagonize apoptosis and telomere dysfunction 
induced by 5-AZA. Thus, telomere-induced dysfunction may contribute to the anti-tumor effect 
of DNMT inhibitors. 
4.2 PAPER Ⅱ: TERT inhibition stimulates COX2 expression and 
synergizes with the COX2 inhibitor to conduct anti-cancer effects 
4.2.1 TERT inhibition activates COX2 promoter and stimulates COX2 
expression via P38 MAPK signaling 
Our first question was whether TERT inhibition will affect the COX2 expression level, and 
whether COX2 forms a positive feedback loop with TERT. Specific TERT siRNA was 
transfected into gastric and cervical cancer cell lines and followed by qPCR and western blot 
to determine the mRNA and protein expression of COX2. Unexpectedly, we observed elevated 
COX2 expression. This elevated COX2 expression was observed at 24h and lasted for the whole 
observation period, which suggests a constitutive rather than transient elevation (Figure 6).  
Our next question was what could be the reason behind this COX2 elevation. We transfected a 
gastric cell line BGC-823 with the reporter construct harboring the COX2 promoter. The COX2 
promoter activity was higher in TERT depleted BGC-823 cells compared with that in control 
cells. 
Previous studies showed that the P38 MAPK signaling played very important roles in COX2 
regulation158-163. We asked whether this was the case here. We detected increased levels of p-
P38 (Phospho P38 at Thr180/Tyr182) in TERT siRNA treated BGC-823 and HeLa cells 
compared with controls. To establish the causal link, we tested the P38MAPK specific inhibitor 
on cells transfected with TERT and control SiRNA. The P38MAPK inhibitor abolished the 
TERT depletion induced COX2 elevation. 
We also measured the telomere length and the results suggested that the TERT depletion 
induced overexpression of COX2 is telomere length independent. 
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Figure 6. Western blot which shows TERT inhibition to stimulate COX2 expression 
4.2.2 TERT depletion synergizes with COX2 inhibition to exert anti-tumor 
effect in gastric cancer cells and mouse xenograft models 
In previous reports, it has been shown that COX2 promotes cancer cell survival and 
proliferation164-168. Thus, it is important to address whether the elevated COX2 expression 
attenuates, whereas COX2 inhibition promotes, the anticancer effect of TERT depletion. We 
transfected TERT specific siRNA into BGC-823 cells followed by their exposure to celecoxib, 
a specific COX2 inhibitor. Flow cytometry analysis showed apoptotic cell death in celecoxib 
and TERT siRNA exposed cells, while neither celecoxib exposure nor TERT siRNA 
transfection alone induced cell death. TERT depletion increased the sensitivity of cancer cells 
to celecoxib induced apoptosis. 
To further investigate the in vivo recapitulation of the in vitro results obtained above wee 
injected nude mice with the TERT depleted and control BGC-823 cells. When analyzing the 
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tumors we could observe that both the control and the TERT depleted cells could generate 
comparable sized tumors in nude mice. 
Then these mice were fed with celecoxib. The celecoxib could not reduce the tumor size from 
mice harboring BGC-823 cells with control shRNA. However, the tumors generated from the 
TERT depleted cells were smaller, suggesting the synergistic anti-tumor effect of TERT 
depletion and COX2 inhibition. 
In summary, our study demonstrated that TERT depletion leads to activated phosph-p38 MAPK 
signaling, increases COX2 promoter activity and elevates the COX2 expression. We evaluated 
the anti-cancer effect of TERT depletion and COX2 inhibition separately and in combination 
both in vitro and in vivo. Knocking down TERT or COX2 inhibition alone could not lead to 
apoptosis in cultured gastric cancer cells while knocking down TERT in combination with 
celecoxib exposure retarded tumor growth in the mouse xenograft model, thus highlighting the 
clinical implications of TERT inhibitor in combination with COX2 inhibition in anti-tumor 
therapy. 
 
4.3 PAPER Ⅲ : The FLT3 tyrosine kinase inhibitor PKC412 
inhibits TERT expression in a MYC-dependent manner in AML 
cells and ectopic expression of TERT attenuates the TKI anti-
tumor efficacy 
4.3.1 The FLT3 TKI inhibits TERT promoter activity, decreases telomerase 
activity and attenuates TERT expression in a MYC-dependent manner. 
PKC412 is a specific inhibitor of FLT3 tyrosine kinase that inhibits FLT3 phosphorylation and 
activation. As TERT plays important roles in carcinogenesis, our first question was what is the 
effect of FLT3 TKI on TERT expression. PKC412 exposure reduced the TERT mRNA 
expression at 0.1µM and almost complete abolishment of TERT mRNA was observed at 24h 
in Mv4,11 cells with FLT3-ITD+ phenotype. Similar results were observed in MOLM13 cells, 
another FLT3-ITD+ AML cell line. In contrast, the wild type FLT3.harboring AML cell line 
HL60 and the cervical cancer cell line HeLa manifest no alterations in TERT mRNA expression 
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levels following PKC412 exposure. In addition, exposure of PKC412 led to declined telomerase 
activity in Mv4,11 and MOLM13 cells. 
Furthermore, we wanted to understand the mechanism behind the decline in TERT mRNA 
expression. A GFP expression vector driven by a TERT promoter was transfected into FLT-
ITD cells, after PKC412 exposure the GFP signal faded to about 50% of the DMSO control, 
which indicates that the PKC412 may inhibit the TERT transcription and lower TERT mRNA 
expression. 
Previous studies have demonstrated a key regulatory role of MYC on TERT expression and we 
further tested the involvement of MYC using the inhibitory effect of PKC412 on TERT 
expression. PKC412 exposure led to a robust decline in MYC mRNA and protein expression 
in FLT-ITD-carrying AML cell lines. To establish the causal link, we transfected the Mv4,11 
cell line with the TERT core promoter harboring vector and the corresponding vector harboring 
TERT core promoter with a deletion in two MYC binding sites. These cells were then subjected 
to PKC412 treatment. PKC412 exposure led to a robust decline in TERT promoter activity, 
while this decline was abolished with the disruption of MYC binding sites. Thus, the above 
observations demonstrate the MYC dependency of TERT inhibition by TKI. 
4.3.2 Ectopic expression of TERT activates alternative tyrosine kinase 
pathway, and abates PKC412 elicited apoptosis in a FLT-ITD+ AML cell line 
Given the above observation, we would like to elucidate whether the ectopic expression of 
TERT could antagonize the anti-cancer effect of TKI. MOLM13 cells were infected with a 
lentiviral TERT expression vector and acquired a constitutive robust expression of TERT. After 
exposure to PKC412, MOLM13-TERT expressing cells exhibited a higher viability than 
control cells. In addition, flow cytometry analysis revealed attenuated apoptosis in MOLM13-
TERT cells. Taken together, these results indicate that the ectopic expression of TERT abates 
the PKC12 elicited apoptosis in FLT-ITD+ AML cells. 
We further explored the possible mechanism of ectopic TERT expression causing the decline 
in PKC412 induced apoptosis. Ectopic TERT expressing cells and control cells were exposed 
to PKC412 and subjected to microarray analysis. We found that the ectopic expression of TERT 
effectively influenced the FLT3 downstream effectors PI3K-AKT and RAS-MAPK, thereby 
antagonizing the PKC412 induced apoptosis (Figure 7). 
In summary, we discovered that tyrosine kinase inhibitor (TKI) reduced TERT expression and 
telomerase activity in a MYC-dependent manner. Ectopic expression of TERT could activate 
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an alternative tyrosine kinase pathway and circumvent the PKC412 elicited apoptotic anti-
cancer effect. 
 
Figure 7. Ectopic expression of TERT activates alternative tyrosine kinase pathways and 
circumvent the TKI blocking effect 
4.4 PAPER Ⅳ:   Bortezomib-induced downregulation of TERT and 
disruption of telomere homeostasis contribute to apoptosis of 
malignant cells 
4.4.1 Bortezomib treatment leads to decline in TERT and TERC expression, 
disruption of shelterin protein expression, telomere shortening and telomere 
dysfunction 
TERT and TERC constitute the core of telomerase holo-enzyme and previous studies have 
shown that bortezomib leads to decline in TERT and TERC expression in subset of myeloma 
cell lines169. We raised the question whether this was also observed in other malignant cell lines. 
32 
 
We treated the gastric cancer cell line BGC-823 and leukemia HEL cell line with bortezomib 
and a sharp decline in TERT mRNA expression was observed at 48 hours. Telomerase activity 
also declined after bortezomib exposure.  
As the shelterin protein complex functions essentially in telomere homeostasis,we explored the 
bortezomib effects on shelterin proteins. In HEL cells, exposure to bortezomib caused reduction 
in TRF1, TRF2, POT1, TPP1, RAP1 and TIN2 mRNA expression. The situation was slightly 
different in BGC-823 cells, where  bortezomib exposure led to decrease in TRF1, TRF2, TPP1, 
POT1 mRNA expression but  to enhancement of RAP1 and TIN2 expression.  
We then analyzed the effect of bortezomib exposure on telomere length and telomere function. 
Flow FISH analysis revealed a significant decline in telomere length in bortezomib exposed 
AML and gastric cancer cells compared to DMSO controls. To illustrate the telomere 
dysfunction, we used co-localization of a very well established DNA damage marker and 
telomere in situ hybridization signal protein 53BP1. In summary, bortezomib treatment 
increased the frequency of telomere dysfunctional foci significantly.  
 
Figure 8. Ectopic expression of TERT overcomes the bortezomib induced telomere 
dysfunction 
33 
 
4.4.2 Ectopic expression of TERT attenuates bortezomib-induced 
downregulation of TRF1, TRF2, TPP1 and RAP1, overcomes telomere 
dysfunction, reduces DNA damage and rescues cancer cells from apoptosis 
Given the above described observations, we further explored whether ectopic expression of 
TERT is capable of preventing bortezomib induced telomere dysfunction. Lenti-viral TERT 
infected HEL and BGC-823 cells stably expressed a two-fold increase of TERT. After exposure 
to bortezomib, TERT expressing cells exhibited much less telomere dysfunction foci compared 
to control cells.  The 53BP1 DNA damage foci also declined in TERT high expressing cells 
compared to control cells (Figure 8). 
We further explored whether ectopic expression of TERT could antagonize the bortezomib 
elicited disruption of shelterin protein expression. In TERT high expressing cell lines, the TRF1, 
TRF2, RAP1 and TPP1 expression level remained essentially the same in both bortezomib 
treated and untreated cells, while POT1 expression still declined and TIN2 transcripts increased. 
We further investigated whether ectopic expression of TERT is able to attenuate bortezomib 
induced apoptosis. Both TERT high expressing and control cells were subjected to bortezomib 
exposure, both cell lines showed a decline in viability in a dose-dependent manner. However, 
more TERT high expressing cells survived compared to control cells. Flow cytometry analysis 
also revealed that higher percentages of control cells underwent apoptosis.  
In summary, our study demonstrates that bortezomib treatment leads to a decline in TERT and 
TERC expression, disruption of shelterin protein expression, telomere shortening and telomere 
dysfunction while ectopic expression of TERT attenuates bortezomib induced down regulation 
of TRF1, TRF2, TPP1 and RAP1, overcomes telomere dysfunction, reduces DNA damage and 
rescues cancer cells from apoptosis.  
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5 CONCLUSION AND PERSPECTIVE 
DNMTIs have been utilized clinically for therapy of hematological malignancies including 
AML but the mechanism of their anti-tumor activity remains to be explored. Bortezomib 
inhibits the ubiquitin/proteasome pathway and thereby exerts its anti-cancer effects, but the 
exact mechanisms remain to be clarified. In addition, the underlying mechanism of the 
clinically utilized TKIs could also be worth to look deeper into. Our study shows a significant 
impact of bortezomib and DNMTI on telomere homeostasis and function, which may contribute 
to bortezomib and DNMTI-mediated anti-tumor efficacy. In addition, here we demonstrated 
that DNMTI, bortezomib and TKI are capable of suppressing TERT expression and shortening 
telomeres thereby promoting apoptotic cell death of AML cells. 
Recent studies revealed multiple biological activities of telomerase or TERT aside from the 
telomere lengthening function. For instance, TERT could facilitate the recruitment of DNA 
repair factors onto DNA double strand break sites, and depletion of TERT results in 
strengthened cell radiation-sensitivity, and declined efficacy for DNA repair. In accordance 
with these reports, we observed that ectopic expression of TERT attenuated DNA damage in 
bortezomib/DNMTI-treated malignant cells. DNA damage is required for bortezomib and 
DNMTI anti-cancer activity. Most likely apoptosis was attenuated in TERT over-expressed 
cells, when exposed to bortezomib or DNMTI. This attenuation may be due to the decreased 
DNA damage mediated by TERT 
More importantly, our study revealed the interfering effect of TERT ectopic expression on 
clinically utilized anti-cancer drugs like DNMTI, TKI and bortezomib. High TERT expression 
could rescue cancer cells exposed to the above inhibitors, which also highlights the necessity 
of exploring TERT inhibitors in combination with these agents in clinical studies. 
A deeper view of the molecular alterations and rewired regulatory signals induced by 
chemotherapeutic and other anti-cancer agents could be helpful  in the future development of  
personalized/targeted anti-cancer treatment. . Uncovering the underlying shared mechanisms 
of multidrug resistance and development of the corresponding inhibitors would greatly 
contribute to novel anti-cancer strategies in the future. 
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